Synergy Pharmaceuticals (SGYP) Holder Hikari Power LTD Has Boosted Its Holding; As Steelcase (SCS) Valuation Declined, Spitfire Capital Has Decreased Its Holding

May 21, 2018 - By Hugh Holland

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Logo

Hikari Power Ltd increased its stake in Synergy Pharmaceuticals Inc (SGYP) by 26.67% based on its latest 2017Q4 regulatory filing with the SEC. Hikari Power Ltd bought 400,000 shares as the company’s stock declined 21.49% with the market. The institutional investor held 1.90 million shares of the health care company at the end of 2017Q4, valued at $4.24M, up from 1.50 million at the end of the previous reported quarter. Hikari Power Ltd who had been investing in Synergy Pharmaceuticals Inc for a number of months, seems to be bullish on the $394.78 million market cap company. The stock decreased 2.44% or $0.04 during the last trading session, reaching $1.6. About 2.41 million shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has declined 62.55% since May 21, 2017 and is downtrending. It has underperformed by 74.10% the S&P500.

Julian Allen decreased its stake in Steelcase Inc (SCS) by 16.58% based on its latest 2017Q4 regulatory filing with the SEC. Spitfire Capital Llc sold 77,067 shares as the company’s stock declined 8.11% with the market. The hedge fund run by Julian Allen held 387,741 shares of the office equipment and supplies and services company at the end of 2017Q4, valued at $5.89M, down from 464,808 at the end of the previous reported quarter. Spitfire Capital Llc who had been investing in Steelcase Inc for a number of months, seems to be less bullish one the $1.67 billion market cap company. The stock increased 0.35% or $0.05 during the last trading session, reaching $14.3. About 437,141 shares traded. Steelcase Inc. (NYSE:SCS) has declined 19.53% since May 21, 2017 and is downtrending. It has underperformed by 31.08% the S&P500.

More important recent Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) news were published by: Seekingalpha.com which released: “Synergy Pharmaceuticals: The Short Covering Has Begun” on May 13, 2018, also Seekingalpha.com published article titled: “Synergy Pharmaceuticals: Q1 Earnings Preview”, Seekingalpha.com published: “Synergy Pharmaceuticals Investors: Refocus Away From Management” on May 17, 2018. More interesting news about Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) was released by: Seekingalpha.com and their article: “Synergy Pharmaceuticals’ (SGYP) CEO Troy Hamilton on Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.

Investors sentiment decreased to 1.22 in 2017 Q4. Its down 0.68, from 1.9 in 2017Q3. It fall, as 21 investors sold SGYP shares while 34 reduced holdings. 24 funds opened positions while 43 raised stakes. 125.65 million shares or 14.56% less from 147.06 million shares in 2017Q3 were reported. The New York-based Tiaa Cref Inv Management Ltd has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Natixis has 66,226 shares. Dekabank Deutsche Girozentrale reported 0% stake. American Grp Inc owns 167,512 shares for 0% of their portfolio. Raymond James Service Advsr owns 46,489 shares. Susquehanna Intl Grp Inc Llp has 0.01% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 14.31M shares. 31,000 were reported by Janney Montgomery Scott Ltd Limited Liability Company. Ruggie Grp Incorporated reported 0% stake. 46,185 were accumulated by Hbk Sorce Advisory Limited Liability Co. Proshare Advsrs Lc invested in 169,802 shares or 0% of the stock. 56,937 are held by Bnp Paribas Arbitrage Sa. Moreover, Legal And General Grp Inc Plc has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Pnc Fincl Serv Grp Inc owns 2,860 shares or 0% of their US portfolio. 180 were reported by Us Commercial Bank De. Gp One Trading Limited Partnership owns 1.52 million shares or 0.02% of their US portfolio.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 46 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, May 14 by BTIG Research. The firm has “Buy” rating by H.C. Wainwright given on Monday, September 25. The company was maintained on Monday, March 5 by H.C. Wainwright. H.C. Wainwright maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Thursday, February 1 with “Buy” rating. Oppenheimer maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) rating on Tuesday, October 10. Oppenheimer has “Buy” rating and $6.0 target. H.C. Wainwright maintained it with “Buy” rating and $7.0 target in Monday, December 4 report. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has “Buy” rating given on Monday, June 12 by H.C. Wainwright. The stock has “” rating by Roth Capital on Thursday, October 29. BTIG Research maintained it with “Buy” rating and $7.0 target in Friday, January 26 report. The rating was maintained by Rodman & Renshaw with “Buy” on Friday, January 20.

Since January 4, 2018, it had 0 buys, and 4 selling transactions for $453,842 activity. Shares for $48,695 were sold by Niemann Jennifer C. 8,000 shares valued at $109,661 were sold by Armbruster Sara E on Wednesday, April 25.

Another recent and important Steelcase Inc. (NYSE:SCS) news was published by Globenewswire.com which published an article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture …” on May 03, 2018.

Among 2 analysts covering Steelcase (NYSE:SCS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Steelcase had 7 analyst reports since September 1, 2015 according to SRatingsIntel. Sidoti upgraded Steelcase Inc. (NYSE:SCS) rating on Friday, September 1. Sidoti has “Buy” rating and $16.0 target. On Friday, November 4 the stock rating was initiated by Seaport Global with “Neutral”. The stock has “Buy” rating by Zacks on Tuesday, September 1. As per Wednesday, September 20, the company rating was downgraded by Sidoti. Raymond James upgraded Steelcase Inc. (NYSE:SCS) on Thursday, March 23 to “Strong Buy” rating. As per Wednesday, December 23, the company rating was downgraded by Raymond James. The firm earned “Strong-Buy – Outperform” rating on Friday, June 23 by Raymond James.

Steelcase Inc. (NYSE:SCS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>